Q-omics provides the consensus-scored MIR4429 profile across patient tissues and cancer cell-line models. MIR4429 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, MIR4429 is differentially expressed in 3, with the highest sampling consensus in PRAD. Additionally, MIR4429 RNA expression shows 8,303 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UCS, PRAD, and GBM as cancer lineages where MIR4429 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR4429 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR4429 survival associations across molecular data types. MIR4429 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR4429 RNA expression–survival associations across cancer types. High MIR4429 expression shows unfavorable associations in UCS, BLCA, STAD, GBM and ESCA, but favorable associations in BRCA. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for MIR4429 RNA expression.
This table summarizes MIR4429 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in UCEC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR4429. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR4429 shows lower tumor expression in UCEC and higher tumor expression in PRAD and LUAD. The PRAD box plot shows higher MIR4429 RNA expression in tumor versus normal tissue (log2 FC = +0.790, t-test p < 0.001).
This table shows molecular features associated with MIR4429 in patient tissues and cancer cell lines. In patient samples, MIR4429 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
